Evidence map›Paper›PMID 37922930›Full record

ArticleThe Lancet. Oncology2023

Single-dose

Rahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, Vadim Koshkin, Rohit Bose, Jonathan Chou, Arpita Desai, Daniel Kwon, Samuel Kaushal, Lauren Trihy and 11 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03805594 (Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer), which is not on this map. Cited by 61 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 5 pooled it
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03805594 phase1completednot on this map

Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab

TypeinterventionalSponsorUniversity of California, San FranciscoRan2019 to 2024Enrolled43ConditionsCastration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate AdenocarcinomaArmsLutetium Lu 177-PSMA-617, Pembrolizumab
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 5 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  9. Radium-223 decreases PD-L1 expression in bone metastases: A study with [European journal of nuclear medicine and molecular imaging · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026
    Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Rahul AggarwalHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. Electronic address: rahul.aggarwal@ucsf.edu.
Stephanie StarzinskiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Ivan de KouchkovskyHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Vadim KoshkinHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Rohit BoseHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Jonathan ChouHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Arpita DesaiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Daniel KwonHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Samuel KaushalHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Lauren TrihyHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Medini RastogiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Robin IppischDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Maya AslamDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Terence FriedlanderHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Felix FengHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
David OhHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Alexander CheungHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Eric SmallHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Michael EvansDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Lawrence FongHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
University of California, San Francisco · US

Funding

Determinants of response to cancer immunotherapyR35CA253175 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lawrence Fong · 2021 to 2026
$5.8M
MELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS A · 2019 to 2025
$3.2M
Qualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7M
Defining the roles of PPARgamma and TGFbeta in regulating NECTIN4 and resistance to NECTIN4-targeting therapiesK08CA273514 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jonathan Chou · 2022 to 2026
$1.3M
Investigating How a Balance of Negative and Positive ETS Factors Controls Prostate OncogenesisK08CA226348 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOSE, ROHIT · 2018 to 2022
$1.3M
Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate CancerR01CA229354 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGGARWAL, RAHUL, HOPE, THOMAS · 2019 to 2020
$735k
Combining immunotherapy with molecularly targeted radiation therapyR01CA276785 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGGARWAL, RAHUL, EVANS, MICHAEL JOHN · 2023 to 2023
$663k
NCI NIH HHS K08 CA226348NCI NIH HHS K08 CA273514NCI NIH HHS R01 CA212148NCI NIH HHS R01 CA229354NCI NIH HHS R01 CA235741NCI NIH HHS R01 CA276785NCI NIH HHS R35 CA253175
6 · The paper itself

Abstract

backgroundCheckpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether a single dose of lutetium-177 [

methodsWe did an open-label, dose-expansion, phase 1 study at the University of California, San Francisco (San Fransisco, CA, USA). Eligible patients were men aged 18 years or older with progressive metastatic castration-resistant prostate cancer who had an Eastern Cooperative Oncology Group performance status of 0 or 1, had progression on one or more androgen signalling inhibitors, and at least three PSMA-avid lesions on

findingsBetween Aug 8, 2019 and May 7, 2022, 43 male patients were enrolled (n=18 part A [six patients per schedule]; n=25 part B), with a median follow-up of 16·5 months (IQR 12·2-21·9). Schedule 1 was selected as the recommended phase 2 schedule for part B, on the basis of safety and feasibility of administration observed in part A. In part B, 14 (56%; 95% CI 35-76) of 25 patients had a confirmed objective response. Two (5%) of 43 patients had a treatment-related adverse event of grade 3 or worse (grade 3 arthritis in schedule 2, grade 3 pneumonitis in schedule 3). One serious adverse event (one death due to aspiration pneumonia) and no treatment-related deaths were observed.

interpretationA single priming dose of

fundingProstate Cancer Foundation, National Cancer Institute, Novartis Pharmaceuticals, and Merck.

Indexed as

Prostatic Neoplasms, Castration-ResistantAntibodies, Monoclonal, HumanizedDipeptidesHeterocyclic Compounds, 1-RingHumansMaleProstate-Specific AntigenTreatment OutcomeAntibodies, Monoclonal, HumanizedDipeptidesHeterocyclic Compounds, 1-RingpembrolizumabProstate-Specific AntigenPSMA-617

Identifiers

PMID37922930
PMCPMC10667020
OpenAlexW4388089396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.